10 March 2016 - Amgen today announced that the U.S. FDA has accepted for review Amgen's supplemental biologics license application for the expanded use of Enbrel (etanercept) to treat paediatric patients with chronic severe plaque psoriasis.

For more details, go to: http://www.amgen.com/media/news-releases/2016/03/fda-accepts-amgens-supplemental-biologics-license-application-for-the-expanded-use-of-enbrel-etanercept-to-treat-pediatric-patients-with-chronic-severe-plaque-psoriasis/